Sugi Predict

Sugi Predict / Compounds / SCHEMBL5936728

SCHEMBL5936728

SCHEMBL5936728

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)C(O)C1(F)F

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 2/20 0.73
▸ ADORA3 P0DMS8 4/20 0.62
▸ PI4KA P42356 2/20 0.62
▸ PI4K2B Q8TCG2 2/20 0.62
▸ PI4K2A Q9BTU6 2/20 0.62
▸ PI4KB Q9UBF8 2/20 0.62
▸ DPP4 P27487 1/20 0.62
▸ MEN1 O00255 1/20 0.62
▸ SLC28A1 O00337 1/20 0.62
▸ MAP3K7 O43318 1/20 0.62
▸ SLC28A2 O43868 1/20 0.62
▸ GAPDH P04406 1/20 0.62
▸ MAPK1 P28482 1/20 0.62
▸ ADORA2B P29275 1/20 0.62
▸ ADORA1 P30542 1/20 0.62
▸ STAT6 P42226 1/20 0.62
▸ KMT2A Q03164 1/20 0.62
▸ SMN1; SMN2 Q16637 1/20 0.62
▸ DOT1L Q8TEK3 1/20 0.62
▸ SLC29A1 Q99808 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5549330 1.00 ADORA2A (0.73) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL29601760 1.00 ADORA2A (0.73) ADORA2AADORA3PI4KAPI4K2BPI4K2A
Phosphoric Acid SCHEMBL21465094 0.94 ADORA2A (0.67) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL14429174 0.92 ADORA3 (0.68) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL4845625 0.89 ADORA2A (0.76) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL546108 0.89 ADORA2A (0.76) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL17117141 0.88 ADORA2A (0.78) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL465644 0.88 ADORA2A (0.78) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL13929067 0.88 ADORA2A (0.78) ADORA2AADORA3PI4KAPI4K2BPI4K2A
SCHEMBL19229274 0.88 ADORA2A (0.71) ADORA2AADORA3PI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 512 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060173174-A1 Difluoronucleosides and process for preparation thereof SICOR, INC. 2006-08-03 — — US claimed
WO-2026106956-A1 DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN MERCK SHARP & DOHME LLC (US) 2026-05-21 — — WO disclosed
US-12629412-B2 Betacoronavirus mRNA vaccines MODERNATX, INC. (US) 2026-05-19 — — US disclosed
US-20260130985-A1 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF ADVANCED RNA VACCINE ARV TECH INC (US) 2026-05-14 — — US disclosed
US-12622960-B2 Varicella zoster virus (VZV) vaccine MODERNATX, INC. (US) 2026-05-12 — — US disclosed
US-20260108595-A1 BETACORONAVIRUS mRNA VACCINES MODERNATX, INC. (US) 2026-04-23 — — US disclosed
EP-4727955-A1 CYSTEINE-SUBSTITUTED RSV-F PROTEINS GlaxoSmithKline Biologicals S.A. (BE) 2026-04-22 — — EP disclosed
EP-3458081-B1 POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 MODERNATX INC (US) 2026-04-15 — — EP disclosed
US-20260097110-A1 BETACORONAVIRUS mRNA VACCINES MODERNATX, INC. (US) 2026-04-09 — — US disclosed
US-20260091104-A1 NUCLEIC ACID VACCINES MODERNATX, INC. (US) 2026-04-02 — — US disclosed
EP-2931319-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF Moderna Therapeutics, Inc. (US) 2015-10-21 — — EP disclosed
EP-2918275-A1 Alternative nucleic acid molecules and uses thereof Roy, Atanu (US) 2015-09-16 — — EP disclosed
WO-2015089511-A2 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2015-06-18 — — WO disclosed
US-20150167017-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. 2015-06-18 — — US disclosed
WO-2015085318-A2 TARGETED ADAPTIVE VACCINES MODERNA THERAPEUTICS, INC. (US) 2015-06-11 — — WO disclosed
WO-2015058069-A1 COMPOSITIONS AND METHODS FOR TOLERIZING CELLULAR SYSTEMS MODERNA THERAPEUTICS, INC. (US) 2015-04-23 — — WO disclosed
WO-2015048744-A2 POLYNUCLEOTIDES ENCODING IMMUNE MODULATING POLYPEPTIDES MODERNA THERAPEUTICS, INC. (US) 2015-04-02 — — WO disclosed
WO-2015038892-A1 POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS MODERNA THERAPEUTICS, INC. (US) 2015-03-19 — — WO disclosed
WO-2014093924-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2014-06-19 — — WO disclosed
US-20060173174-A1 Difluoronucleosides and process for preparation thereof SICOR, INC. 2006-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097110-A1 BETACORONAVIRUS mRNA VACCINES RNMT, RNGTT, METTL16 ADORA2A 717/4885ADORA3 714/4885PI4KA 1898/4885
US-12629412-B2 Betacoronavirus mRNA vaccines RNMT, RNGTT, METTL16 ADORA2A 828/4885ADORA3 1063/4885PI4KA 1526/4885
US-20060173174-A1 Difluoronucleosides and process for preparation thereof DUT, NUDT1, DPYD ADORA2A 221/4885ADORA3 216/4885PI4KA 3529/4885
US-20260091104-A1 NUCLEIC ACID VACCINES RNMT, NSUN2, AMPD1 ADORA2A 62/4885ADORA3 90/4885PI4KA 2105/4885
US-20260108595-A1 BETACORONAVIRUS mRNA VACCINES RNMT, METTL16, NSUN2 ADORA2A 2246/4885ADORA3 1556/4885PI4KA 2441/4885
US-12622960-B2 Varicella zoster virus (VZV) vaccine NSUN2, RNMT, RNGTT ADORA2A 3858/4885ADORA3 3561/4885PI4KA 1271/4885
US-20260130985-A1 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF UPF1, NSUN2, CD4 ADORA2A 2670/4885ADORA3 2683/4885PI4KA 4408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.